Fidelity mutual fund rides big pharma profits

Boasting a 12-month return of 27.3%--more than 10% better than both the Dow Jones Industrial Average and the S&P 500 returns--the Fidelity Select Pharmaceutical Portfolio recognizes "a lot of profit potential for the drug industry," despite patent expirations and generic competition. The fund comprises companies that research, manufacture, sell or distribute drugs. Its five-year return of 35.9% whupped the Dow's 9.7% and the S&P 500's 1.5%. The top five holdings: Pfizer, Valeant, Merck, Johnson & Johnson and Novo Nordisk. Story

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.